APA (7th ed.) Citation

SJ, C. (2025). Second MEK Inhibitor Shows Promise in Neurofibromatosis Type 1 With Symptomatic Plexiform Neurofibromas Signaling Hope for Other RASopathies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(6), 730. https://doi.org/10.1200/JCO-24-02375

Chicago Style (17th ed.) Citation

SJ, Cook. "Second MEK Inhibitor Shows Promise in Neurofibromatosis Type 1 With Symptomatic Plexiform Neurofibromas Signaling Hope for Other RASopathies." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 6 (2025): 730. https://doi.org/10.1200/JCO-24-02375.

MLA (9th ed.) Citation

SJ, Cook. "Second MEK Inhibitor Shows Promise in Neurofibromatosis Type 1 With Symptomatic Plexiform Neurofibromas Signaling Hope for Other RASopathies." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 6, 2025, p. 730, https://doi.org/10.1200/JCO-24-02375.